Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

IMPACT Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours

Coordinator
Impact Biotech Ltd, Israel
Runs
1 December 2024 to 30 November 2026
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101188848

What the project is doing

In the project's own words, from its summary on CORDIS.

UTUC is a non-systemically treatable cancer that forms in the renal pelvis or ureter, frequently recurring due to ineffective systemic chemotherapy. With 5-10% of urothelial cancers being UTUC, current surgical treatment solutions pose significant hardships on patients and decrease their quality of life. Our proprietary solution, Padeliporfin-VTP therapy, offers a minimally invasive and effective alternative to surgery.

This therapy delivers an inactive photosensitizer drug that is precisely activated in the tumour micro-environment by non-thermal laser light, immediately impeding the tumour's blood supply, leading to cell death with minimal effect on healthy tissues. This treatment not only effectively eliminates tumours, but also preserves organ functionality for potential future treatments. This project is led by a team of accomplished professionals in the pharmaceutical and biopharma industry, which solidifies our capability in innovating best-in-class therapeutic solutions.

Utilising this funding, we aim to achieve regulatory approval (TRL9), scale production, and achieve market penetration in a market projected to reach €4.39B by 2032.

Topics

Who is involved

OrganisationCityCountryRole
Impact Biotech LtdNess TzionaIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI